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Oxidative stress is regarded as a pathogenic factor in hyperthyroidism. Our purpose was to determine the relationship between the
oxidative stress and the inﬂammatory cytokines and to investigate how melatonin aﬀects oxidative damage and cytokine response
in thyrotoxic rats. Twenty-one rats were divided into three groups. Group A served as negative controls. Group B had untreated
thyrotoxicosis,andGroupCreceivedmelatonin.Serummalondialdehyde(MDA),glutathione(GSH),glutathionereductase(GR),
glutathione peroxidase (GPx), and nitric oxide derivates (NO
•x), and plasma IL-6, IL-10, and TNF-alpha were measured. MDA,
GSH, NO
•x, IL-10, and TNF-alpha levels increased after L-thyroxine induction. An inhibition of triiodothyronine and thyroxine
was detected, as a result of melatonin administration. MDA, GSH, and NO
•xl e v e l sw e r ea l s oa ﬀected by melatonin. Lowest TNF-
alphalevelswereobservedinGroupC.Thisstudydemonstratesthatoxidativestressisrelatedtocytokineresponseinthethyrotoxic
rat. Melatonin treatment suppresses the hyperthyroidism-induced oxidative damage as well as TNF-alpha response.
Copyright © 2009 Balahan Makay et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Hyperthyroidism is associated with an increased metabolic
rate due to increments in the rate of oxygen consumption
in target tissues [1]. Acceleration of aerobic metabolism by
thyroidhormonesenhancesthegenerationofoxidativestress
[2]. Oxidative stress is regarded as a pathogenic factor in
hyperthyroidism. Clinical and experimental studies reported
increased levels of free oxygen radicals and a decreased
antioxidant status in thyrotoxicosis [3–6].
Free oxygen radicals are general mediators of signal
transduction pathways, which are able to induce cytokine
production from various cell types [7–10]. Studies attesting
to the role of antioxidants, of which potentially inhibit
the activation of oxidant-mediated transcription factors,
reported that these antioxidants also prevent the tran-
scriptional activation of inﬂammatory cytokines [11–13].
These studies suggest that antioxidants may play a role
in decreasing the immune response by suppressing the
oxidative stress. Since these ﬁndings may be of clinical
relevance in the thyrotoxic patient, herein we aimed to inves-
tigate (1) whether oxidative stress aﬀects the production of
cytokines IL-6, IL-10, and TNF-alpha and (2) whether these
alterations are inhibited by melatonin-based antioxidative
therapy.
2. Methods
Twenty-one 12-week-old male Wistar albino rats with a
body weight of 250–300g were included in the study. All
were housed in groups of 7 in identical wire-bottomed
cages with a 12 hour day-night cycle, at a constant room
temperature of 24 ± 1◦C. The animals were acclimatized
to these conditions for 10 days before the experiment.
Standard rat food and water was freely available. All rats
were treated according to the UFAW Handbook on the Care2 Mediators of Inﬂammation
and Management of Laboratory Animals (Blackwell, 7th ed,
Blackwell Science, Iowa, 1999) and Principles of Laboratory
Animal Care (NIH publication no. 86-23, revised 1985). The
protocol was approved by Ege University Ethics Committee
of Experimental Studies and Ege University , Department of
Experimental Surgery.
Rats were randomized to the following groups according
to the treatment to which each was subjected and were
sacriﬁced at the end of the 3-weeks treatment:
(1) Group A (n = 7), the sham group, was not
subjected to any procedure, except receiving daily
intraperitoneal injections of 0.9% saline solution;
(2) Group B (n = 7), the untreated (control) group,
underwent intraperitoneal L-thyroxine administra-
tion for induction of hyperthyroidism, for 21 days
and at a daily dose of 0.2mg/kg. L-thyroxine was
dissolved using 0.01N NaOH, and the ﬁnal solution
was prepared with 0.9% saline solution;
( 3 )G r o u pC( n = 7), the treatment group, underwent
L-thyroxine as in Group B and besides, received daily
( e a c h2 4h o u r s )3m g / k gm e l a t o n i nf o r2 1d a y s( I l s a n
Iltas Laboratories, Istanbul), intraperitoneally.
2.1. Laboratory Measurements. All evaluations were done
by a single biochemist blinded to the study. Blood was
collected through heart puncture to estimate thyroid func-
tion tests (TSH, FT3,a n dF T 4), oxidative stress mark-
ers (malondialdehyde [MDA], glutathione [GSH], glu-
tathione reductase [GR], glutathione peroxidase [GPx],
and nitric oxide [NO
•]), and cytokines (IL-6, IL-10 and,
TNF-alpha). Blood samples were centrifuged at 2500g
for 5 minutes at room temperature. The serum was
removed and stored at −80
◦C for later studies. Free T3
(triiodothyronine) (FT3), free T4 (thyroxine) (FT4), and
TSH (thyroid stimulating hormone) analyses were carried
out with a chemiluminescent enzyme radioimmunometric
assay by using the IMMULATE 2000 automated hormone
analyzer (Diagnostic Products, Los Angeles, Calif, USA).
The reproducibility of the methods, established before
the study by conducting 2 additional independent exper-
iments, was good with clear normative limits and a 95%
agreement.
2.2. Measurement of MDA. Lipid peroxidation (LPO) is
frequentlyinvestigatedinbiomedicalresearch,andtheassays
for thiobarbituric acid-reactive substances (TBARSs) are
more widely used than any other index of LPO in biological
samples. Thiobarbituric acid reacts with LPO aldehydes,
such as malondialdehyde (MDA). Therefore, assessment
of TBARS is a useful index of oxidative deterioration
and LPO determination in body ﬂuids. MDA levels were
determinedspectrophotometricallyat532nmbythemethod
of Ohkowa et al. [14]. MDA formed a colored complex in
the presence of thiobarbituric acid, which was detectable
by measurement of absorbance at 532nm. Absorbance
was measured with Shimadzu UV-160 spectrophotometer.
1,1 ,3,3  tetraethoxypropane was used as a standard. Levels
were calculated as nmol/mL.
2.3. Measurement of GSH. Total glutathione content was
measured according to the method of Tietze [15]. In brief,
0.5mL sample or standard solution was mixed with 0.25mL
of 1mol/L sodium phosphate buﬀer (pH 6.8) and 0.5mL
5-5 -dithiobis-(2-nitrobenzoic acid) (DTNB, 0.8g/L in the
phosphate buﬀer) for 5 minutes. Then, the absorbance was
measured at 412nm using a Shimadzu UV-160 spectropho-
tometer. The GSH concentration was determined using
standard aqueous solutions of GSH. Results were expressed
as mg/dL.
2.4. Measurement of GR. Glutathione reductase was assayed
by following the oxidation of NADPH at 340nm at 37
◦C
[16]. The reaction was initiated by the addition of 50μL
supernatant to 1mL of assay mixture containing 50mmol/L
T r i s ,p H7 . 6 ,1 0 0 μmol/L Na2EDTA, 4mmol/L GSSG, and
120μmol/L NADPH. A blank cuvet was prepared in which
the sample was replaced with water. The reaction was linear
for 2 to 3 minutes. Hemoglobin in erythrocyte lysates was
estimated using the method of Drabkin and Austin [17].
Activity in samples was normalized for hemoglobin content
and is expressed in U/g Hb.
2.5. Measurement of GPx. Glutathione peroxidase activity
was determined by a minor modiﬁcation of the method
of Paglia and Valentine [18]. A 50μL supernatant was
transferred to a 1mL quartz cuvet, containing 950μLo f
the reaction mixture (Tris buﬀer, 50mmol/L, pH 7.6,
containingperliter,1mmolofNa2EDTA,2mmolofreduced




25μLo fH 2O2, 8.8mmol/L (% 30). The decrease in NADPH
absorbance at 340nm was followed for 3 minutes. The
nonenzymic reaction rate (blank) was determined by substi-
tuting water for the supernatant. The decrease in NADPH
absorbance was recorded. Hemoglobin was evaluated as
described above. Activity in samples was normalized for
hemoglobin content and is expressed in U/g Hb.
2.6. Measurement of NO
• Derivative Content. NO
•x (nitrite
+ nitrate) was assayed by a modiﬁcation of cadmium-
reduction method as mentioned by Navarro-Gonz` alves [19].
The nitrite produced was determined by diazotization of
sulphanilamide and coupling to naphthlethylene diamine.
For the measurement of NO
•x, a 400μL sample was
denaturedbyadding 80μL30% ZnSO4 solution,stirring and
then centrifuging at 10000xg for 20 minutes at 4◦C. First,
we activated Cd granules using CuSO4 solution in glycine-
NaOH buﬀer. Then, 100μL of deproteinized samples and
standards were added. This reaction, using pretreatment of
samples to reduce nitrate to nitrite, can be accomplished by
catalytic reactions using enzyme or Cd. The samples were
analyzed spectrophotometrically using a microplate reader
and quantiﬁed automatically against KNO3 standard curve.
Results were expressed as μM/L.
2.7. Measurement of IL-6. Plasma IL-6 levels were deter-
mined via a commercial rat ELISA kit (IBL Co., Ltd.Mediators of Inﬂammation 3
Table 1: Comparison of thyroid function tests.
n Group A Group B Group C
FT3 (pg/mL) 7 1.49 ±0.26 8.68 ±3.69
∗ 3.28 ±2.98
∗∗
FT4 (ng/dL) 7 1.44 ±0.44 4.62 ±2.18
∗ 1.94 ±1.22
∗∗
TSH (μIU/mL) 7 0.25 ±0.02 0.15 ±0.01 0.20 ±0.36
Values were expressed as mean ± standard deviation.
∗P<. 01; signiﬁcant when compared with Group A.
∗∗P<. 01; signiﬁcant when compared with Group B.
Table 2: Comparison of MDA, GSH, GR, GPx, and NO
• derivate levels.
Group n MDA (μmol/L) GSH (mg/dL) GR (U/g Hb) GPx (U/g Hb) NO (μM/L)
A7 3 .42 ±1.47 0.26 ±0.06 0.83 ±0.34 4.02 ±1.51 6.72 ±1.55
B7 4 .80 ±1.23
∗ 0.43 ±0.06
∗ 1.05 ±0.39 3.48 ±0.76 66.0 ±58.54
∗
C7 2 .31 ±0.71
∗∗ 0.35 ±0.07
∗∗ 0.78 ±0.31 3.88 ±1.17 47.11 ±15.18
∗∗
Values were expressed as mean ± standard deviation.
∗P<. 01; signiﬁcant when compared with Group A.
∗∗P<. 01; signiﬁcant when compared with Group B.
Hamburg, Germany), catalogue and lot number 17196. The
test results were calculated by bioelisa reader ELx800 using
standard curve. The kit measurement range was 11.72–
750pg/mL. Interassay values were calculated for three dif-
ferent measurement values (34.83, 71.71, and 293.31pg/ml),
and CV values were found to be 2.3%, 1.9%, and 1.7%,
respectively, (n = 10). Besides, intra-assay values deter-
mined three diﬀerent measurement values (33.57, 70.45, and
293.45pg/mL), and CV values were found to be 8.8%, 7.7%,
and 4.9%, respectively, (n = 10). We did not use haemolysed
samples.
2.8. Measurement of IL-10. IL-10 levels were determined via
a commercial human ELISA kit (IMMUNOTECH; Beckman
Coulter Company, Marseille Cedex, France). Test results
were calculated by bioelisa reader ELx800 using standard
curve. The kit measurement range was 0–2000pg/ml. Kits’
performance characteristics were performed. Intra-assay
precision was determined by assaying sera 10 times, and
CVs ranged between 3.3 and 4.0%. Interassay precision was
determined by assaying samples 10 times in independent
assays. CVs ranged between 5.6 and 8.6%. We did not use
haemolysed samples.
2.9. Measurement of TNF-Alpha. TNF-α levels were deter-
mined via a commercial rat ELISA kit (IBL Co., Ltd.
Hamburg , Germany), catalogue number 17194. Test results
were calculated by bioelisa reader ELx800 using standard
curve. The kit measurement range was 0.39–25ng/mL.
Kits’ performance characteristics were performed. Interassay
valueswerecalculatedforthreediﬀerentmeasurementvalues
(0.36,1.69,and7.03ng/mL),andCVvalueswerefoundtobe
8.8%, 3.0%, and 1.0%, respectively, (n = 10). Besides, intra-
assay values determined three diﬀerent measurement values
(0.33,1.69,and7.03ng/mL),andCVvalueswerefoundtobe
8.8%, 3.0%, and 1.0%, respectively, (n = 10). Besides, intra-
assay values determined three diﬀerent measurement values
(0.33, 1.68, and 6.7ng/mL), and CV values were found to
be 9.1, 9.5, and 4.3, respectively, (n = 10). We did not use
haemolysed samples.
2.10. Statistical Analysis. All analyses were performed by
using SPSS Statistical Analysis software (release 10.0,
Chicago, Ill, USA). All data are expressed as mean ±
standard deviation. To search diﬀerence between the groups,
Kruskal-Wallis one-way analysis was used. Depending on
the homogeneity of the variances, Mann-Whitney U-test
and Bonferonni post hoc test were used in pair comparison.
Correlations between oxidative stress parameters and serum
concentrations of cytokines were studied by regression
analysis. P-values of less than .05 were considered to be
signiﬁcant.
3. Results
3.1. Thyroid State. The thyroid state of diﬀerent groups of
animals was characterized by the data reported in Table 1.
The values indicate signiﬁcant rises in FT3 and FT4 levels
after L-thyroxine administration (P<. 01). It was also
found that melatonin treatment signiﬁcantly decreased the
concentrations of FT3 and FT4 when compared to rats with
hyperthyroidism in the untreated group (P<. 01).
3.2. Oxidative Stress and Response to Oxidative Stress. MDA,
GSH, GR, GPx, and NO
•x levels of control and treatment
groups are presented in Table 2. Comparison among the
g r o u p sr e v e a l e dt h a tM D A ,G S H ,a n dN O
•xl e v e l si n
hyperthyroid rats were signiﬁcantly higher than the negative
control and treatment groups (P<. 01).
3.3. Plasma Cytokine Concentration. Levels of both IL-10
andTNF-alphaweresigniﬁcantlyenhancedafterL-thyroxine
administration (P<. 01), while the rise in IL-6 was
insigniﬁcant (P<. 05). Melatonin treatment was associated
with signiﬁcant decreased TNF-alpha levels (P<. 01)4 Mediators of Inﬂammation
Table 3: Comparison of plasma cytokine levels.
Group n IL-6 (pg/mL) IL-10 (pg/mL) TNF-alpha (ng/mL)
A 7 324.66 ±26.28 33.53 ±10.03 0.76 ±0.04
B 7 345.99 ±109.20 51.99 ±17.43
∗ 0.88 ±0.1
∗
C 7 333.33 ±38.92 56.00 ±10.33 0.75 ±0.05
∗∗
Values were expressed as mean ± standard deviation.
∗P<. 01; signiﬁcant when compared with Group A.
∗∗P<. 01; signiﬁcant when compared with Group B.
(Table 3). There was a signiﬁcant correlation between IL-
10 concentration and both oxidative stress parameters MDA
and NO (r = 0.48, P<. 05 and r = 0.39, P<. 01, resp.).
A signiﬁcant correlation also existed between serum TNF-
alpha and MDA (r = 0.49, P<. 01) as well as TNF-alpha
and NO level (r = 0.69, P<. 01). No correlations were found
between TNF-alpha and thyroid hormone levels (P>. 05).
4. Discussion
The ﬁndings of the study suggest that (1) thyrotoxicosis
stimulates the oxidative stress response and the production
of inﬂammatory cytokines (IL-10 and TNF-alpha), (2)
there is a relationship between oxidative stress parameters
and inﬂammatory cytokines, (3) melatonin prevents the
increase in FT3 and FT4 caused by chronic T4 injection,
and (4) melatonin-based antioxidative treatment inhibits
thyroidhormoneinducedincreasesinMDA,GSH,NO
•,and
TNF-alpha levels. Meanwhile, to our knowledge, the latter
observation, that melatonin acts on TNF-alpha levels, seems
novel. We hypothesized that reactive oxygen intermediates,
that were induced by thyrotoxicosis, act as a signal for the
release of cytokines like IL-6, IL-10, and TNF-alpha. We
documented the increased oxidative stress and antioxidant
system capacity, together with response to allopurinol, in
diﬀerenttimeintervals,inanotherpaper,whichissoongoing
to be published elsewhere.
Previous studies have provided evidence that free rad-
icals increase during hyperthyroidism [3–6]. Whatever the
pathways are, it is clear that T3-induced liver free-radical
generation occurs in concomitance with enhanced respira-
tory burst activity and chemiluminescent response in both
experimental and human studies [20, 21]. The evidence
that oxidative stress occurs related to thyroid hormone
induction is supported in the current study, since we
have demonstrated signiﬁcant increases in oxidative stress
parameters like MDA and NO
•x. Although some modalities
have been suggested to prevent the development of oxidative
stress during thyrotoxicosis, no management has yielded
promising uniform success, clinically [22–24].
Oxidative stress is paralleled by impaired antioxidant
mechanisms; glutathione is one of these important systems
[25]. In one of the few studies related to GSH in hyperthy-
roidism,GSHwasstimulatedinanexperimentalmodel[26].
In these studies, it was concluded that free radicals appear
to stimulate GSH production in prolonged oxidative stress.
This explanation seems plausible, since biochemical data of
our study showed an increase in GSH.
Several previous reports have tried to address the
contribution of thyrotoxicosis to the rise in inﬂammatory
cytokines such as IL-1, IL-6, IL-10, and TNF-alpha [13, 27–
34]. Although controversial results, almost all these studies
suggest that cytokines may play important roles in the
processofhyperthyroidism.Theonlyreportinvestigatingthe
eﬀect of TNF-alpha levels on thyroid hormone kinetics is the
one by Ongphiphadhanakul et al. These investigators found
that TNF-alpha might inhibit the peripheral generation of
T3 from T4 and act as an autocrine factor by decreasing
thyroidal generation and release of T3 [33]. Our data is
not in accordance with this ﬁnding, since no correlation
was found between TNF-alpha levels and thyroid hormones.
In the present study, we demonstrated a signiﬁcant IL-10
and TNF-alpha release after thyroid hormone induction,
while the increase of IL-6 was insigniﬁcant. Thus, our results
do not support any role for IL-6 in the pathogenesis of
thyrotoxicosis.
IL-6 acts as a systemic hormone [35] that may mediate
the well-documented inhibitory eﬀect of IL-1 on thyroid
cell functions [36]. In regard to IL-6, our ﬁndings are in
agreement with the data presented by Senturk et al. [29]
and Burggraaf et al. [32], since we could not present a
statistically signiﬁcant diﬀerence between thyrotoxic rats and
control subjects. We suggest that this may be attributed
to the duration of thyroid hormone induction or the
consequence that since IL-6 can be bounded to plasma
proteins, which may camouﬂage IL-6 immunoreactivity in
serum, as previously suggested [29].
In contrast to IL-6, IL-10 is one of the most potent anti-
inﬂammatory cytokines [37]. IL-10 interferes with cellular
immunity in several ways and is known to attenuate the
expression and/or production of proinﬂammatory cytokines
[38]. TNF-alpha is expressed as one of these cytokines [39].
Our data did not support this, since both IL-10 and TNF-
alpha levels were elevated after T4 induction. Interestingly,
proinﬂammatory stimuli like TNF-alpha enhance its secre-
tion without any inﬂuence of IL-6 [40]. There is a lack
of evidence regarding IL-10 and nonautoimmune thyroid
disorders. Data presented by de la Vega et al. supported
that Il-10 levels in multinodular glands did not reach a
signiﬁcant diﬀerence versus normal subjects [41]. But the
study population they studied wasonly 15, whereeachgroup
consisted of 5 patients.
The link between free oxygen radicals and inﬂammatory
processes in hyperthyroidism was studied previously by
Fern´ andez et al. [27]. They addressed that the eﬀects of
thyroid hormones on the expression of nuclear factor kappaMediators of Inﬂammation 5
B( N F - κB) ligand are involved in the cytokine response seen
in hyperthyroidism. There is evidence that T3administration
to rats show induced expression of NF-κB-responsive genes
for TNF-alpha and IL-10 [13]. This was correlated with
increases in the serum levels of the cytokines in the same
study.
Even though deleterious eﬀects of NO
• in oxidative
processes [42], its production is accepted to be induced
by proinﬂammatory cytokines [43]. In our model, thyro-
toxicosis resulted in obvious increased NO
•x levels, and
there was a correlation between NO
•x and cytokine levels.
This correlation suggests a link between NO and cytokine
response in the thyrotoxic rat. This might simply mean that
while a probable contributory role for these cytokines is
suggested, it seems not to be the only factor involved in
the complex pathogenesis in thyrotoxicity-related oxidative
stress.
Melatonin, after discovered as a free radical scavenger in
1993[44],hasbeenreportedtobeprotectiveinvariousmod-
elsofoxidativestress,boththroughitsfreeradicalscavenging
eﬀect as well as by directly increasing antioxidant activity
[45]. Although melatonin has been proposed to be useful
forthepreventionofoxidativestressduringhyperthyroidism
[23,46],toourknowledge,therehasbeennoreportstudying
the eﬀects of antioxidative therapy on serum concentrations
of IL-6, IL-10, and TNF-alpha in the thyrotoxic rat. The
hypothesis that melatonin is protective against free oxygen
radicals was further supported by our observation that after
melatonin treatment, increased MDA, GSH, and NO
•xl ev e l s
decreased signiﬁcantly. Besides, thyroid hormone and TNF-
alpha levels after melatonin treatment were lower than in
untreated rats, suggesting an inhibitory eﬀect of melatonin
on T3,T 4, and TNF-alpha. The decrement in TNF-alpha
levels did not relate with the decrease of thyroid homone
levels, suggesting a direct antioxidant eﬀect of melatonin
on TNF-alpha. Studies on the hypothesis of an inhibitory
eﬀect of melatonin on thyroid hormones documented
contradictory results [47, 48]. In fact, melatonin is known
with its stimulating eﬀect on antioxidative enzymes, such
as GR and GPx [49]. These enzymes convert oxidized
glutathione to GSH, leading to increased GSH activity.
However, in our study, melatonin administration did not
result in increased GR and GPx levels. Moreover, it resulted
in decreased GSH. This paradox might be attributed to
diﬀerences in type and manner of melatonin administration.
Melatonin suggests an immunotherapeutic potential, since it
inhibitsTNF-alpha.Whateverthemechanismis,thefactthat
melatonin counteracts the increase of TNF can help toward
anunderstanding ofthecomplex natureofTNF induction in
hyperthyroidism.
Collectively, data presented in this work support a
link between thyroid hormone-induced oxidative stress
and cytokine response. It provides new insights into the
role of IL-10 and TNF-alpha in thyrotoxicosis. Therapy
for increased oxidative stress with melatonin signiﬁcantly
reduces triiodothyronine, thyroxine, IL-10, and TNF-alpha
levels. The fact that circulating cytokines might diﬀer from
those in diﬀerent tissues is a limitation of this study.
Although the expression of cytokines seems to be involved
with thyrotoxicosis-induced oxidative stress, this relation
remains to be studied in future qualitative studies.
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